Elevated circulating sclerostin concentrations in individuals with High Bone Mass, with and without LRP5 mutations

Celia L Gregson; Ken E S Poole; Eugene V McCloskey; Emma L Duncan; Jörn Rittweger; William D Fraser; George Davey Smith; Jonathan H Tobias

doi:10.1210/jc.2013-3958

Elevated circulating sclerostin concentrations in individuals with High Bone Mass, with and without LRP5 mutations

Celia L Gregson, Ken E S Poole, Eugene V McCloskey, Emma L Duncan, Jörn Rittweger, William D Fraser, George Davey Smith, Jonathan H Tobias

Research output: Contribution to journal › Article › peer-review

14 Citations (Scopus)

Abstract

Context: The role and importance of circulating sclerostin is poorly understood. High Bone Mass (HBM) caused by activating LRP5 mutations has been reported to be associated with increased plasma sclerostin concentrations; whether the same applies to HBM due to other causes is unknown. Objective: To determine circulating sclerostin concentrations in HBM. Design: Case-control study Participants: 406 HBM index cases were identified by screening DXA databases from 4 UK centers (n=219,088), excluding significant osteoarthritis/artefact. Controls comprised unaffected relatives & spouses. Main measure(s): Plasma sclerostin, lumbar spine L1, total hip and total body DXA, and radial and tibial pQCT (subgroup only). Results: Sclerostin concentrations were significantly higher in both LRP5 HBM and non-LRP5 HBM cases, compared with controls; mean[SD] 130.1[61.7] and 88.0[39.3], vs. 66.4[32.3]pmol/L, both p

Original language	English
Pages (from-to)	2897–2907
Journal	The Journal of Clinical Endocrinology and Metabolism
Volume	99
Issue number	8
DOIs	https://doi.org/10.1210/jc.2013-3958
Publication status	Published - 25 Feb 2014

Access to Document

10.1210/jc.2013-3958

Biochemical Markers of bone metabolism and Paget's Disease of bone
Fraser, W.
Medical Research Council
3/05/12 → 30/04/13
Project: Research

Cite this

Gregson, Celia L ; Poole, Ken E S ; McCloskey, Eugene V ; Duncan, Emma L ; Rittweger, Jörn ; Fraser, William D ; Smith, George Davey ; Tobias, Jonathan H. / Elevated circulating sclerostin concentrations in individuals with High Bone Mass, with and without LRP5 mutations. In: The Journal of Clinical Endocrinology and Metabolism. 2014 ; Vol. 99, No. 8. pp. 2897–2907.

@article{d15d81f439544708942bf5a2cc57ac0c,

title = "Elevated circulating sclerostin concentrations in individuals with High Bone Mass, with and without LRP5 mutations",

abstract = "Context: The role and importance of circulating sclerostin is poorly understood. High Bone Mass (HBM) caused by activating LRP5 mutations has been reported to be associated with increased plasma sclerostin concentrations; whether the same applies to HBM due to other causes is unknown. Objective: To determine circulating sclerostin concentrations in HBM. Design: Case-control study Participants: 406 HBM index cases were identified by screening DXA databases from 4 UK centers (n=219,088), excluding significant osteoarthritis/artefact. Controls comprised unaffected relatives & spouses. Main measure(s): Plasma sclerostin, lumbar spine L1, total hip and total body DXA, and radial and tibial pQCT (subgroup only). Results: Sclerostin concentrations were significantly higher in both LRP5 HBM and non-LRP5 HBM cases, compared with controls; mean[SD] 130.1[61.7] and 88.0[39.3], vs. 66.4[32.3]pmol/L, both p",

author = "Gregson, {Celia L} and Poole, {Ken E S} and McCloskey, {Eugene V} and Duncan, {Emma L} and J{\"o}rn Rittweger and Fraser, {William D} and Smith, {George Davey} and Tobias, {Jonathan H}",

year = "2014",

month = feb,

day = "25",

doi = "10.1210/jc.2013-3958",

language = "English",

volume = "99",

pages = "2897–2907",

journal = "Journal of Clinical Endocrinology & Metabolism",

issn = "0021-972X",

publisher = "The Endocrine Society",

number = "8",

}

Elevated circulating sclerostin concentrations in individuals with High Bone Mass, with and without LRP5 mutations. / Gregson, Celia L; Poole, Ken E S; McCloskey, Eugene V; Duncan, Emma L; Rittweger, Jörn; Fraser, William D; Smith, George Davey; Tobias, Jonathan H.

In: The Journal of Clinical Endocrinology and Metabolism, Vol. 99, No. 8, 25.02.2014, p. 2897–2907.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Elevated circulating sclerostin concentrations in individuals with High Bone Mass, with and without LRP5 mutations

AU - Gregson, Celia L

AU - Poole, Ken E S

AU - McCloskey, Eugene V

AU - Duncan, Emma L

AU - Rittweger, Jörn

AU - Fraser, William D

AU - Smith, George Davey

AU - Tobias, Jonathan H

PY - 2014/2/25

Y1 - 2014/2/25

N2 - Context: The role and importance of circulating sclerostin is poorly understood. High Bone Mass (HBM) caused by activating LRP5 mutations has been reported to be associated with increased plasma sclerostin concentrations; whether the same applies to HBM due to other causes is unknown. Objective: To determine circulating sclerostin concentrations in HBM. Design: Case-control study Participants: 406 HBM index cases were identified by screening DXA databases from 4 UK centers (n=219,088), excluding significant osteoarthritis/artefact. Controls comprised unaffected relatives & spouses. Main measure(s): Plasma sclerostin, lumbar spine L1, total hip and total body DXA, and radial and tibial pQCT (subgroup only). Results: Sclerostin concentrations were significantly higher in both LRP5 HBM and non-LRP5 HBM cases, compared with controls; mean[SD] 130.1[61.7] and 88.0[39.3], vs. 66.4[32.3]pmol/L, both p

AB - Context: The role and importance of circulating sclerostin is poorly understood. High Bone Mass (HBM) caused by activating LRP5 mutations has been reported to be associated with increased plasma sclerostin concentrations; whether the same applies to HBM due to other causes is unknown. Objective: To determine circulating sclerostin concentrations in HBM. Design: Case-control study Participants: 406 HBM index cases were identified by screening DXA databases from 4 UK centers (n=219,088), excluding significant osteoarthritis/artefact. Controls comprised unaffected relatives & spouses. Main measure(s): Plasma sclerostin, lumbar spine L1, total hip and total body DXA, and radial and tibial pQCT (subgroup only). Results: Sclerostin concentrations were significantly higher in both LRP5 HBM and non-LRP5 HBM cases, compared with controls; mean[SD] 130.1[61.7] and 88.0[39.3], vs. 66.4[32.3]pmol/L, both p

U2 - 10.1210/jc.2013-3958

DO - 10.1210/jc.2013-3958

M3 - Article

C2 - 24606091

VL - 99

SP - 2897

EP - 2907

JO - Journal of Clinical Endocrinology & Metabolism

JF - Journal of Clinical Endocrinology & Metabolism

SN - 0021-972X

IS - 8

ER -

Elevated circulating sclerostin concentrations in individuals with High Bone Mass, with and without LRP5 mutations

Abstract

Access to Document

Projects

Biochemical Markers of bone metabolism and Paget's Disease of bone

Cite this